1. Scrip
  2. >>Scrip Asks

Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials

Decentralization, Diversity And Data Analytics Are Drivers Of Change

 
• By Eleanor Malone

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.

Scrip Asks, Part 5
• Source: Alamy

Evolution of clinical trials was a major theme among executives who at the end of 2021 shared their predictions for 2022. Remote, or decentralized, trials was a common talking point, as was the harnessing of technological advances in capturing and analyzing data.

Ross Pettit, deputy president of Eisai Co., Ltd. precision oncology subsidiary H3 Biomedicine Inc, summed up some of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

More from Scrip

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.